34 results about "Fusobacterium" patented technology

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

The present invention addresses the problem of providing a composition for controlling bacteria belonging to the genus Fusobacterium among the intestinal flora. The present invention provides a composition for controlling a bacterium belonging to the genus Fusobacterium in the intestinal flora, the composition comprising a bacterium belonging to the family Lactobacillus. The bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum), and the bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum). It is preferable that the bacterium belonging to the family Lactobacillus belong to a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, the genus Limosilbacilli, the genus Liiilbacilli, the genus Lactobacillus lactis, the genus Lactobacillus casei, and the genus Lactobacillus plantarum, and that the bacterium belonging to the family Lactobacillus is a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus lactis, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus and the genus Lactobacillus acidophilus.

Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. They subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial stmins by administering a compound that binds to and / or inhibits one or more toxins produced thereby.

A probiotic composition for inhibiting the onset and progression of colorectal cancer, comprises one or more of a culture supernatant of Faecalibacterium prausnitzii (Fp) cells, live Fp cells, or non-viable Fp cells，wherein the probiotic composition comprises at least one metabolite of Fp, wherein the at least one metabolite is hypoxanthine. A use of the probiotic composition or hypoxanthine for manufacturing of a medicament for inhibiting the onset and progression of colorectal cancer.

The invention discloses a biomarker for predicting severe treatment of a COVID-19 patient and application of the biomarker, and relates to the technical field of biomedicine. According to the invention, a COVID-19 patient severity prediction or auxiliary prediction model which is obtained by constructing biomarkers including Gemelia haemolsos, Streptococcus sp.A12, Fusobacterium pseudoperiodontium, Gemelia mollissima, Villonella atypical, Villonella rogosa and Prevotella melaninogena is found, the model is used for predicting and evaluating the severity of the COVID-19 patient, the sensitivity is high, and the specificity is good. The invention further discloses a method for predicting and evaluating the severity of the COVID-19 patient severity, and the method has the advantages that the method can be used for predicting and evaluating the severity of the COVID-19 patient severity;

To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None

A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences and methods of use are also provided.

The invention relates to a multifunctional bacterial bio-conjugate integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation and a preparation method thereof, CaO2 nanoparticles (CaO2 NPs) are synthesized through a calcium salt deposition method, a photosensitizer chlorin e6 (Ce6) is loaded on the surface of the CaO2 NPs through an ingenious design, then tannic acid (TA) is used for packaging, and the multifunctional bacterial bio-conjugate is prepared. The stable core-shell structure (TAat-CaO2 / Ce6) is obtained. A large number of phenolic hydroxyl groups, aromatic rings and galloyl groups on the surface of TA are utilized to form chemical coupling with rich functional groups on the surface of bacteria, so that the TA is loaded on the surface of the bacteria, and effective combination of a TA-coated CaO2 / Ce6 compound and fusobacterium nucleatum (Fn) is realized; and finally, the multifunctional bacterial bio-conjugate Fn-TA (at) CaO2 / Ce6 integrating targeted delivery, oxygen generation, photodynamic therapy and immune activation is successfully constructed.

The present invention relates to genetically modified strains of Clostridium which provide an improved combination of replication and physiological properties useful for a variety of clinical and industrial applications. In particular, clinical grade spores produced from the Clostridium strains described herein can be efficiently stored, formulated, and advantageously used for the prevention and / or treatment of medical conditions such as cancer.

The application discloses a prebiotic composition for proliferating intestinal beneficial bacteria and a preparation method thereof, and comprises the following raw materials in parts by weight: partially hydrolyzed composite glue 35-45 parts, resistant starch of green banana 30-40 parts, enzymatic okra polysaccharide 15-25 parts, and tea polyphenol 3-5 parts. The composition realizes efficient proliferation of intestinal beneficial bacteria and comprehensive and positive regulation of intestinal microenvironment by scientifically compounding partially hydrolyzed composite glue with a specific molecular weight, resistant starch of green banana, enzymatic okra polysaccharide and tea polyphenol. The four components with complementary functions and different effects can not only more efficiently proliferate traditional beneficial bacteria such as bifidobacterium and lactobacillus, but also effectively nourish butyric acid bacteria such as prasrmanella, and inhibit the growth of harmful bacteria, thereby having the functions of significantly improving intestinal flora disorder caused by ampicillin and promoting the generation of short-chain fatty acids and maintaining the intestinal barrier.

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

The present invention discloses an application of tea lovage polysaccharide in the preparation of a drug for regulating intestinal flora in inflammatory bowel disease, and belongs to the technical field of polysaccharide extraction process optimization and intestinal flora regulation. Specifically, the present invention provides an economical and efficient extraction process and new use of tea lovage polysaccharide for the preparation of a preparation or composition. By increasing the relative abundance of probiotic flora, reducing the relative abundance of harmful bacteria, regulating the structure of intestinal flora, etc., the symptoms of intestinal flora disorder in inflammatory bowel disease are alleviated and treated. Tea lovage polysaccharide improves ulcerative colitis in mice by upregulating the relative abundance of probiotics such as Bacteroides and Faecalibacterium prausnitzii, and downregulating the relative abundance of pathogenic bacteria such as Proteobacteria, Gammaproteobacteria, Enterobacteriaceae and Escherichia, thereby reversing the abnormal proliferation of bacteria in mice with inflammatory bowel disease and improving the disordered intestinal flora in mice with inflammatory bowel disease.

The present invention addresses the problem of controlling a fusobacterium bacterium by means of a method which is believed to have little influence on beneficial bacteria. The present invention provides a composition for controlling bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora, comprising any one selected from the group consisting of flavonoids and sugar transporters thereof that dissociate a compound represented by formula I in the digestive tract, and the compounds represented by formula I. The composition can be used for controlling the bacteria belonging to the genus fusobacterium in the digestive tract, particularly in the oral and intestinal flora.

The invention discloses an application of a fusobacterium specific antibacterial peptide in preparation of a medicine for improving the anti-tumor immunotherapy effect of a PD-1 antibody. It is found that the fusobacterium specific antibacterial peptide combined with the PD-1 antibody has a remarkable tumor growth inhibition effect. According to the invention, the application range of the fusobacterium specific antibacterial peptide is expanded, and the fusobacterium specific antibacterial peptide has important significance for developing a novel anti-tumor pharmaceutical composition and establishing a novel efficient immunotherapy method.

Methods comprising obtaining a biological sample and extracting nucleic acids from it are disclosed. The methods process the nucleic acids for DNA sequencing and identify in the DNA sequencing data a plurality of amplicon sequence variants (ASV). The methods record the relative abundance of each ASV and classify, using a machine learning algorithm, each ASV according to one of a set of taxonomies. The set of taxonomies includes a pathobiont bacteria subset consisting of genus level groups Eggerthella group, Ruminococcus torques group, Ruminococcus gnavus group, Coprobacillus group, Streptococcus group, Bilophila group, Actinomyces group, Desulfovibrio group, Atopobiaceae group, Veillonella group, Enterococcus group, Escherichia-Shigella group, Campylobacter group, Enterobacteriaceae group, and Fusobacterium group. Based on the relative abundance of the ASV classified as pathobiont bacteria, a numerical indication of the health of the subject is calculated. Based on the numerical indication, the methods deliver to the subject a customized intervention.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.

The present invention relates to directly fed microorganisms for controlling diseases caused by a species of the genus Fusobacterium or Arcanobacterium in an animal. More specifically, the present invention relates to isolated Bacillus strains 86, 300, 101, 235, 177 and 102, as well as strains having all identifying characteristics of these strains, their use for comprising the above use.

The present invention relates to systems and methods for estimating an individual's Faecalibacterium prausnitzii (Fprau) amounts and for providing personalized recommendations to maintain or improve the Fprau. In several embodiments of the invention, the individual's Fprau amounts are estimated based on their Food FrequencyQuestionnaire (FFQ) records. In several embodiments, the methods are implemented by a computer system. In several embodiments of the invention, personalized recommendations and dietary advice are given to the individual to maintain or improve said individual's Fprau.

The invention discloses a complex microbial inoculant containing bifidobacterium and application of the complex microbial inoculant. Comprising two or more of bifidobacterium lactis BL9, bifidobacterium longum subsp. Longum KS1, clostridium pratensis GZSY3214, Leuconostoc mesenteroides PM10, and Gluconacetobacter xylinus Q1, and further comprises a preparation method of the bifidobacterium lactis BL9, a preparation method of the bifidobacterium longum subsp. Longum KS1, a preparation method of the bifidobacterium longum subsp. Longum GZSY3214, a preparation method of the bifidobacterium longum, a preparation method of the bifidobacterium longum, a preparation method of the bifidobacterium longum and a preparation method of the bifidobacterium longum, and a preparation method of the bifidobacterium longum. The complex microbial inoculant can be used for preparing milk powder, weight-losing food and fruit and vegetable beverages, and is wide in application range.

The invention discloses bacteroides simplex capable of regulating and controlling abundance of clostridium pralaense in intestinal tracts and application of the bacteroides simplex, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a strain of Bacteroides simplex CCFM1370, the Bacteroides simplex CCFM1370 is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number of the Bacteroides simplex CCFM1370 is GDMCC No: 64267. The bacteroides simplex CCFM1370 can effectively adjust alpha diversity and beta diversity of flora in fermentation liquor in an in-vitro simulated colon fermentation system, and the level of butyrate in the fermentation liquor and the absolute bacterial count of clostridium praeparatum are improved. And the abundance of the clostridium praeparatum can be remarkably increased by co-culturing with the clostridium praeparatum in an in-vitro YCFA culture medium. Therefore, the bacteroides simplex CCFM1370 provided by the invention has huge application prospect and commercial value in the preparation of products (such as drugs) for regulating the abundance of clostridium praeparatum so as to prevent and / or treat related diseases.

The invention relates to a method for determining the suitability of a product for use in a cosmetic or pharmaceutical formulation for topical use, the product being a chemical or biochemical substance of any type (S) or a composition of chemical or biochemical substances of any type (C), the method comprising a step of suspending, in a single culture medium suitable for bacterial growth, the following species: C. xerosis, M. luteus, S. epidermidis, C. acnes and S. mitis, in order to form, in the co-culture medium, a co-culture of the consortium of bacterial strains of the five aforementioned species, in proportions close to those found on the skin; followed by a step of bringing the co-culture, in the co-culture medium, into contact with the product for a period of between seven and nine hours, and a step of calculating a score (Sc): Sc = Σ(RL species X), wherein RL species X represents the following logarithmic reduction for a given bacterial species, and a step of determining the suitability of the product for use in a cosmetic or pharmaceutical formulation for topical use, wherein the determination step consists in selecting the substance (S) or the composition (C) when the score (Sc) is less than or equal to 5 and greater than or equal to -5 and rejecting the substance (S) or the composition (C) when the score (Sc) is greater than 5 or less than -5 and the individual RL species X for each species are between -3 and 3.

This invention belongs to the field of microbial technology, specifically relating to an oral microorganism for identifying taste sensitivity, its identification method, and its application. The microorganisms include... Haemophilus genus, Fusobacterium genus, Aggregatibacter genus, Lachnoanaerobaculum genus and Oribacterium One or more of the above-mentioned microorganisms are identified, and the abundance of one or more of these microorganisms is significantly positively correlated with taste sensitivity. The application method is as follows: 1) Collect oral biological samples; 2) Extract DNA from saliva samples and perform sequencing analysis; 3) Detect the abundance of microbial assemblage; 4) Verify the correlation between key characteristic oral microorganisms and individual taste sensitivity. The advantage is that it is a non-invasive and non-surgical method to determine individual differences in taste sensitivity, aiming to achieve efficient, low-cost, and accurate identification of individual taste sensitivity.

The application discloses a multiple digital PCR detection kit for diagnosing liver cirrhosis intestinal flora disorder. The kit is used for diagnosing pathogens including Soehngenella, Escherichia, Romboutsia, Clostridium, Fusobacterium and Mucispirillum in intestinal flora. By using the kit, specific strains in intestinal microflora in vivo can be detected to diagnose liver cirrhosis, thereby providing a new idea for diagnosis and treatment of liver cirrhosis.

The invention discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The cervical cancer plasma circulating microbial marker combination disclosed by the invention is prepared from prevotella, stenosiella, chlamydia trachomatis, peptostreptococcus, fusobacterium, campylobacter and haemophilus. Cervical cancer patients and healthy people are verified by using the cervical cancer plasma circulating microbial marker combination disclosed by the invention, the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, so that the cervical cancer plasma circulating microbial marker combination disclosed by the invention can be used for effectively distinguishing the cervical cancer patients from the healthy people; the method is suitable for early screening of cervical cancer and has remarkable clinical screening application value.

Aspects of the disclosure encompass compositions and therapeutic methods for treating subjects having gastrointestinal disorders. The compositions provided herein can be formulated as live biotherapeutic products (LBP), fecal microbiota transplant (FMT) products and FMT enrichment compositions, probiotics and food products, and comprise one or more of the bacterial species Faecalibacterium prausnitzii, Bifidobacterium adolescentis, Bifidobacterium longum, Eubacterium rectale or combinations thereof. In certain aspects, an individual is determined to be a suitable recipient for these therapies based on classification of the taxa profile of their microbiome.

[Problem] The purpose of the present invention is to provide a composition capable of inhibiting diseases other than oral diseases. [Solution] The present invention is a growth inhibitor for Fusobacterium bacteria, and contains cyclodextran and / or a derivative thereof. The inhibitory effect of Fusobacterium bacteria contributes to the treatment and prevention of ulcerative colitis, cirrhosis, obesity, colon cancer, esophageal cancer, oral cancer, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, premature birth, endometriosis, and the like.

Provided is at least one agent selected from the group consisting of (a) a gut microbiota or a metabolite thereof and (b) an antibody or a derivative thereof for use in immunotherapy of colorectal cancer. The gut microbiota includes at least one selected from the group consisting of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Alistipes putredinis, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The gut microbiota or the metabolite thereof and / or the antibody or the derivative thereof in this application can enhance the anti-tumor effect of immunotherapy, and demonstrate the functions of regulating the immune microenvironment and improving sensitivity to tumor immunotherapy.

Described herein are compounds and compositions for use in treatment or prevention of an inflammatory bowel disease, gastrointestinal cancer, or a systemic bacterial infection in a subject in need thereof. The subject may be colonized by one or more pathogenic bacterial strains such as B. fragilis, E. faecalis, or C. perfringens. In certain aspects, the disclosure provides a method of diminishing the pathogenic effects of these bacterial strains by administering a compound that binds to and / or inhibits one or more toxins produced thereby.

The objective is to provide a composition that can suppress diseases other than oral diseases. [Solution] The present invention is a growth inhibitor for Fusobacterium bacteria containing cyclodextran and / or its derivatives. Due to its inhibitory effect on Fusobacterium bacteria, it contributes to the treatment and prevention of ulcerative colitis, liver cirrhosis, obesity, colorectal cancer, esophageal cancer, oral cancer, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, premature birth, and endometriosis ulcers.

This application relates to the field of bioassay technology and specifically discloses a combination of microbial markers for predicting the sensitivity of colorectal cancer to neoadjuvant chemotherapy and its application. The combination of microbial markers includes Treponema, Staphylococcus, Streptococcus, Gemella, and Fusobacterium. This application analyzes the composition of the microbial community in the tumor microenvironment of colorectal cancer patients to identify microbial markers associated with sensitivity to neoadjuvant chemotherapy. Based on the microbial marker combination disclosed in this application, it is possible to accurately predict patients who are insensitive to neoadjuvant chemotherapy, reduce treatment risks, and reduce ineffective treatments, providing a reliable basis for developing precise and personalized treatments.